Testing of the first personalized vaccine for a type of cancer on a British patient
The world’s first skin cancer vaccine, tested on patients by the UK’s National Health Service, is described by experts as one of the most exciting advances in modern cancer treatment, produced with great technical skill and precision.
The target of this vaccine is individuals who have had high-risk melanomas. This is the world’s first personalized mRNA vaccine for skin cancer.
It is made individually for each person, aiming to identify cancer cells and prevent the recurrence of the disease in the individual. The tumor sample is sequenced for DNA, and artificial intelligence plays a role as well, making it arguably smarter than a vaccine.
This is the final stage of the vaccine’s trial. In the second stage of testing, this vaccine significantly reduces the risk of cancer recurrence.